<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>SCIENCE AND TECHNOLOGY COMMITTEE (COMMONS)</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Medical Schools Council and Association of UK University Hospitals response </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0006)</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">1.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Medical Schools Council (MSC) represents the interests and ambitions of UK medical schools as they relate to the generation of national health, wealth and knowledge through biomedical research and the profession of medicine. The membership of the Medical Schools Council is made up of the Heads or Deans of the 33 UK undergraduate medical schools, plus the postgraduate London School of Hygiene and Tropical Medicine.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">1.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The Association of UK University Hospitals (AUKUH) is the key leadership body across the UK promoting the unique interests of University Hospitals. Its purpose is to represent the unique role and interests of UK University Hospital Trusts in the tripartite mission of service, teaching and research in partnership with other national bodies. There are currently 44 member Trusts.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">1.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the opportunity to submit evidence to the Science and Technology Committee inquiry into antimicrobial resistance (AMR). In summary, we believe that:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The primary cause of increased AMR is the unrestricted use of antibiotics in hospitals, in the community and in animals. There are other significant factors, including increased globalisation.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Gaps in current knowledge include understanding of biochemical and molecular mechanisms, quality epidemiological data and an evidence base for interventions to alter practice and behaviour.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Increased and more targeted research funding is required to address these gaps. Due to poor incentives for the pharmaceutical industry to pursue this area, it may be necessary to explore shared public-private costs. Stimulating academic:industry consortia or collaborations could be particularly beneficial.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Greater antibiotic stewardship and education are the twin strands to pursue in designing interventions.</span></li><ul type="square" style="margin:0pt; padding-left:0pt"><li style="font-family:Wingdings; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 103.63pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There needs to be a further investment in infection specialists in hospitals to allow input at the point of antimicrobial prescribing decisions (and indeed guide appropriate diagnosis). The recent Cochrane review</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> has demonstrated that this type of intervention is much more effective than 'restrictive' interventions</span></li><li style="font-family:Wingdings; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 103.63pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There isn't the same degree of challenge about individual antibiotic prescriptions in the community. Community pharmacists need to be empowered to question antibiotic choices, </span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">duration and have access to </span><span style="font-family:'Times New Roman'; font-size:11pt">locally agreed guidelines (developed jointly between secondary &amp; primary care)</span></li><li style="font-family:Wingdings; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 103.63pt; padding-left:7.97pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Education about antibiotic prescribing needs to be improved both for hospital prescribers &amp; GPs.</span></li></ul><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK has experience which could be ‘exported’ to assist other health systems around the world.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Government’s 2013-18 Strategy is welcome and could be enhanced through greater focus on intervention science.</span></li></ul><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">How has antimicrobial resistance developed in the past decade?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">2.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There has been a significant rise in the problem of resistance in recent years, primarily among Gram negative bacteria (we would note that the problem in Gram positive bacteria has diminished slightly).  The principal explanation is the unrestricted use of antibiotics in hospitals, in the community and in animals. This is a result of a “vicious cycle” of increasing resistance needing the use of ever-more powerful antibiotics, which in turn drive the emergence of increasingly resistant bacteria.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">2.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Increased globalisation has had a significant impact. Just as we are familiar with the idea that the huge increase in international travel can quickly spread transmissible infections around the world (witness the SARS outbreak as one of many examples), exactly the same thing happens at the level of antibiotic resistant bacteria. International travel (of people, animals and even foodstuffs) and issues such as “medical tourism” can easily spread Multi-Drug Resistant (MDR) bacteria around the world.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">2.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Other drivers include:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">the practice of over-the-counter antibiotic sales;</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">that in many countries the need to pay for antibiotics means that an inadequate course of treatment is taken and/or that unused antibiotics are kept for use at the patient’s discretion on a later date [both increasing the chance of inappropriate use and increased resistance];</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">poor hand hygiene;</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">ineffective cross-infection procedures.</span></li></ul><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the gaps in our knowledge about antimicrobial resistance?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">3.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There are many fundamental questions that remain unanswered, in several domains:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Basic science</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">level:</span><span style="font-family:'Times New Roman'; font-size:11pt"> there have been considerable advances in the molecular genetics of transmissible drug resistance, but less work on the biochemical and molecular mechanisms that are affected.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Epidemiological data</span><span style="font-family:'Times New Roman'; font-size:11pt"> are erratic and often of poor quality; worldwide secular trends are often difficult to identify and we are usually unable to analyse outbreaks of </span><span style="font-family:'Times New Roman'; font-size:11pt">multi-drug resistant infection with sufficient resolution to reconstruct the modes and routes of transmission and identify individual cross infection events.  Questions such as the exact relationship between consumption and resistance and the interactions between animals and humans (in both directions) remain poorly understood. A key remaining question is: why are there such marked differences between countries which have largely similar prescribing habits?</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 67.66pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Intervention science</span><span style="font-family:'Times New Roman'; font-size:11pt"> is at a very primitive stage: the evidence base for different strategies to alter practice (i.e. behavioural studies) in terms of infection control, or prescribing habits is a major area that needs attention.</span></li></ul><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We would note that in recent years there has been renewed interest in basic microbiology and immunology. There is much good work in these areas and more investment would be welcome to continue this. Similarly, there has been investment in research into the use of whole-genome sequencing to track the spread of resistant organisms, which has placed the UK at the forefront of such efforts globally. However, continued investment is needed before such approaches can become routine and there is scope for additional research into more effective molecular epidemiological and ecological approaches to track the emergence and spread of resistance, including culture-independent approaches and the transmission of resistant organisms through asymptomatic patients and the environment.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">In contrast, the evidence base in intervention science (as noted above) is much weaker. Therefore, it is likely that there would be a bigger impact from increased resource in this area.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Fundamental questions about clinical practice remain. For instance, how does duration of antibiotic therapy impact the emergence of resistance? Further emphasis on non-antibiotic based approaches would be very valuable. This would include anti-virulence or anti-pathogenicity approaches, and of course vaccine development.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.4.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">It is important to acknowledge that a tension exists in the commercial development of new antibiotics. The pharmaceutical industry is often reluctant to commit the very considerable resources required to develop and launch a new antibiotic when:</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 90pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">the indications are likely to be highly restricted because academia will insist that “new” antibiotics are reserved for a small number of difficult-to-treat or MDR organisms, and;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 90pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">infections are usually relatively short lived so that the financial returns available from long term use of new drugs are not available.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.5.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">If this difficulty is to be circumvented, then some innovative ideas will be necessary. It may be beneficial to consider the approach beginning to emerge in oncology, whereby costs are shared between the public and private sector. It is no coincidence that the number of novel antibiotic classes developed in recent years has slowed considerably. Stimulating academic/industrial consortia or collaborations in drug development in this area would be valuable.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">5.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We believe antibiotic stewardship and education are the key over-arching measures required. Together they describe a series of interventions which include:</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Nationwide campaigns to reduce the use of antibiotics, in particular during viral infections, to engender change in behaviour of prescribers, and patients/consumers.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Controlling and regulating the availability of antibiotics in hospitals and in primary care, based on advice and guidance from pharmacists and infection specialists.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A decrease in the prophylactic usage in animals (growth promoters).</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Protected antibiotics for humans.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Limiting over the counter usage.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Fighting against counterfeit products.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Nationwide campaigns to improve measures that decrease cross transmission of resistant and susceptible micro-organisms. In particular with hand hygiene, in both the community, the hospitals and in livestock.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Rapid diagnostic tests to improve antibiotic selection.</span></li></ul><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">6.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">This is unambiguously a global problem. There is clearly a major role for trans-national organisations such as European Centre for Disease Prevention and Control and the World Health Organization, and we believe that they recognise the challenge.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">6.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The UK (in part through the prominent position taken by the Chief Medical Officer) has taken a leading role, but there is considerably more to do.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">6.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The advantages that we have in the UK as a result of a national health service have provided us with much experience and expertise that could usefully be “exported” to other countries that currently have a much less regulated (and therefore less tractable) system of health care. This includes many developed as well as less developed nations.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:130%; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></li></ol><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">7.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We credit the Government’s acknowledgment of the scale of the problem and the high priority that this issue has been given.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">7.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The “7 key areas” for future action correctly identify the major elements of a strategy that must encompass both basic science as well as education.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 39.6pt; text-align:justify; text-indent:-21.6pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">7.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">We believe that the majority of the points identified in the 2013-18 strategy have been picked up in the comments above. However, we would argue that greater focus on ‘implementation science’ would be worthwhile. This is often of less interest to both academia and to funders because it rarely involves fundamental insights or novel hypotheses. However, experience shows that simple questions about how best to use antibiotics, when and for how long they should be given, how to incentivise doctors (and educate patients) to restrict antibiotic use and the like can often yield substantial benefits. A greater steer from Government to the National Institute for Health Research to prioritise these types of studies might pay significant dividends</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="font-size:11pt; line-height:130%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:right"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">Davey P, Brown E, Charani E, Fenelon L,</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">Gould IM,</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">Holmes A, Ramsay CR,</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">Wiffen PJ,Wilcox</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">M.</span><span style="font-family:'Arial Narrow'; font-size:10pt"> (2013)</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">‘</span><span style="font-family:'Arial Narrow'; font-size:10pt">Interventions to improve</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">antibiotic prescribing pr</span><span style="font-family:'Arial Narrow'; font-size:10pt">actices for hospital inpatients’</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt; font-style:italic">Cochrane Database of Systematic Reviews</span><span style="font-family:'Arial Narrow'; font-size:10pt">, Issue 4. Art. No.: CD003543.</span><span style="font-family:'Arial Narrow'; font-size:10pt"> </span><span style="font-family:'Arial Narrow'; font-size:10pt">DOI: 10.1002/14651858.CD003543.pub3.</span></p></body></html>